Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 studyMatthew S. Davids, Jennifer R. Brown, Benjamin L. Lampson et al.|The Lancet Oncology|2021Cited by 102
Venetoclax plus dose-adjusted R-EPOCH for Richter syndromeMatthew S. Davids, Jennifer R. Brown, Kerry A. Rogers et al.|Blood|2021Cited by 75
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk DiseaseMatthew S. Davids, Jennifer R. Brown, Christine E. Ryan et al.|Journal of Clinical Oncology|2024Cited by 40
A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patientsMatthew S. Davids, Jennifer R. Brown, David C. Fisher et al.|Leukemia|2020Cited by 36
Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)Benjamin L. Lampson, Matthew S. Davids, Jon Arnason et al.|Blood|2019Cited by 31